Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine

Journal of Virology

Volumn 86, Issue 4, 2012, Pages 2239-2250

  Qureshi, Huma ^a,b   Ma, Zhong Min ^a,b   Huang, Ying ^c   Hodge, Gregory ^b   Thomas, Michael A ^d   Dipasquale, Janet ^d   Desilva, Veronique ^a,b   Fritts, Linda ^a,b   Bett, Andrew J ^e   Casimiro, Danilo R ^e   Shiver, John W ^e   Robert Guroff, Marjorie ^d   Robertson, Michael N ^e   Mcchesney, Michael B ^b   Gilbert, Peter B ^c   Miller, Christopher J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AD5 SIVMAC239 GAG PROTEIN VACCINE; AD5 SIVMAC239 NEF PROTEIN VACCINE; AD5 SIVMAC239 POL PROTEIN VACCINE; CYTOKINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; POL PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE;

ADENOVIRUS 5; ADENOVIRUS INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS LOAD; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; DEFECTIVE VIRUSES; DISEASE MODELS, ANIMAL; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, NEF; GENETIC VECTORS; HIV; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; MACACA MULATTA; MALE; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALIA; HUMAN ADENOVIRUS TYPE 5; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84863116109     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06175-11     Document Type: Article

References (47)

1. + T cells in vivo. J. Virol. 80:6801-6809.
2. Buchbinder SP, et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
3. Buge SL, et al. 1997. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 71:8531-8541.
4. Casimiro DR, et al. 2010. Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge. J. Virol. 84:2996-3003.
5. Casimiro DR, et al. 2005. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79:15547-15555.
6. Curlin ME, et al. 2011. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS 25:153-158.
7. Damen M, et al. 2008. Real-time PCR with an internal control for detection of all known human adenovirus serotypes. J. Clin. Microbiol. 46:3997-4003.
8. Daniel MD, et al. 1985. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228:1201-1204.
9. Desrosiers RC, Letvin NL. 1987. Animal models for acquired immunodeficiency syndrome. Rev. Infect. Dis. 9:438-446.
10. + T cells. Nature 417:95-98.
11. Fellay J, et al. 2011. Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. J. Infect. Dis. 203:773-779.
12. Fitzgerald DW, et al. 2011. An Ad5-vectored HIV-1 vaccine elicits cellmediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J. Infect. Dis. 203:765-772.
13. + T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J. Intern. Med. 265:67-77.
14. + T cells mediate protection from vaginal SIV challenge in rhesus macaques immunized with attenuated SHIV89.6. J. Virol. 82:11181-11196.
15. Hudgens MG, Gilbert PB. 2009. Assessing vaccine effects in repeated low-dose challenge experiments. Biometrics 65:1223-1232.
16. Hudgens MG, et al. 2009. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J. Infect. Dis. 200:609-613.
17. Keele BF, et al. 2009. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206:1117-1134.
18. Kirmaier A, et al. 2010. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol. 8:e100046Z.
19. Klessig DF, Grodzicker T. 1979. Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells map in the viral gene encoding the 72K DNA binding protein. Cell 17:957-966.
20. Letvin NL, et al. 1985. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 230:71-73.
21. Letvin NL, et al. 2004. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J. Virol. 78:7490-7497.
22. Liang X, et al. 2005. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J. Virol. 79:12321-12331.
23. Lim SY, et al. 2010. TRIM5α modulates immunodeficiency virus control in rhesus monkeys. PLoS Pathog. 6:e1000738.
24. Liu J, et al. 2010. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J. Virol. 84:10406-10412.
25. + immunodominance may influence the ability of Mamu-B*08-positive macaques to naturally control simian immunodeficiency virus SIVmac239 replication. J. Virol. 82:1723-1738.
26. Loffredo JT, et al. 2007. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J. Virol. 81:8827-8832.
27. Ma ZM, et al. 2011. SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma. AIDS Res. Hum. Retrovir. 12:1259-1269.
28. + T cells in multiple tissues during acute SIV infection. Nature 434:1093-1097.
29. McDermott AB, et al. 2005. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques. J. Virol. 79:15556-15566.
30. McElrath MJ, et al. 2008. HIV-1 vaccine-induced immunity in the testof-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905.
31. Miller CJ. 1994. Mucosal transmission of SIV. Curr. Top. Microbiol. Immunol. 188:107-122.
32. Miller CJ, et al. 1989. Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J. Virol. 63:4277-4284.
33. Morgan C, et al. 2008. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 5:e173.
34. Mothe BR, et al. 2003. Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 77:2736-2740.
35. + T cells is not predictive of simian immunodeficiency virus virulence. J. Immunol. 179:3035-3046.
36. Patterson LJ, et al. 2003. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hrsimian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J. Virol. 77:8607-8620.
37. Pine SO, et al. 2011. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One 6:e18526.
38. Priddy FH, et al. 2008. Safety and immunogenicity of a replicationincompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46:1769-1781.
39. Rolland M, et al. 2011. Genetic impact of vaccination on breakthrough HIV-1 sequences from the Step Trial. Nat. Med. 17:366-371.
40. Shiver JW, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335.
41. Sprangers MC, et al. 2003. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41:5046-5052.
42. Stone M, et al. 2010. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J. Virol. 84:7083-7095.
43. Stone M, et al. 2009. Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus. Virology 392:260-270.
44. + T cell depletion and viral replication in SIV infection. Science 280:427-431.
45. Weatherall D. 2006. The use of non-human primates in research. Academy of Medical Sciences, Medical Research Council, The Royal Society and Wellcome Trust, London, United Kingdom.
46. Wilson NA, et al. 2009. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J. Virol. 83:6508-6521.
47. Yeh WW, et al. 2011. TRIM5 modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys. J. Virol. 85:10389-10398.